Timing is everything, especially when considering an investment in Exelixis. As a key player in the biotechnology sector, Exelixis boasts a robust operating margin of 43.37%, indicating efficient management and strong potential for future profitability. With a market capitalization of $8.1 billion and a current valuation of $7.15 billion, the stock appears reasonably priced, especially when you consider its promising profit margin of 17.38%. The company's return on equity stands at 15.06%, reflecting its ability to generate profit from shareholders' investments. While the trailing PE ratio of 24.03 suggests the stock isn't undervalued, the target price of $29.80 offers room for growth. With a solid book value per share of $7.43 and minimal debt to equity at 0.07%, Exelixis presents a compelling case for those looking to capitalize on its potential in the coming year. Many baby boomers might not be fully aware of the potential within the biotechnology sector, so let's take a closer look at Exelixis. We'll explore how this company could fit into your investment portfolio. How is Exelixis valued in 2024? We'll provide insights into its valuation to help investors make informed decisions about including it in their holdings.
We determine the current worth of Exelixis using both absolute as well as relative valuation methodologies to arrive at its intrinsic value. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Exelixis based exclusively on its
fundamental and basic
technical indicators. By analyzing Exelixis's
financials, quarterly and monthly indicators, and related drivers such as
dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Exelixis's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Exelixis. We calculate exposure to Exelixis's
market risk, different
technical and
fundamental indicators, relevant financial multiples and ratios, and then
comparing them to Exelixis's related companies.
Exelixis Investment Alerts
Exelixis investment alerts and warnings help investors to get more proficient at understanding not only critical technical and fundamental signals but also the significant portfolio-centered indicators. These indicators include beta, alpha, and other risk-related measures that will help you in monitoring Exelixis performance across your portfolios.Please check all
investment alerts for Exelixis
Exelixis Valuation Ratios as Compared to Competition
Our valuation model uses many indicators to compare Exelixis value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Exelixis competition to find
correlations between indicators driving the intrinsic value of Exelixis.
Exelixis Gross Profit
Exelixis Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Exelixis previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Exelixis Gross Profit growth over the last 10 years. Please check Exelixis'
gross profit and other
fundamental indicators for more details.
What is driving Exelixis Investor Appetite?
Exelixis reported the previous year's revenue of 1.83
B. Net Income was 207.76
M with profit before overhead, payroll, taxes, and interest of 1.55
B.
| 2016 | 2021 | 2022 | 2024 (projected) |
Payables Turnover | 1.53 | 2.18 | 2.15 | 2.29 | Days Of Inventory On Hand | 211.05 | 189.79 | 87.16 | 180.3 |
Margins Breakdown
Exelixis profit margins show the degree to which it makes money. Margin indicators are used not only by investors but also by creditors or Exelixis itself as indicators of financial health and management effectiveness. Please look more closely at the different varieties of Exelixis profit margins.
0.21
Operating Profit Margin
| Pretax Profit Margin | 0.22 |
| Operating Profit Margin | 0.21 |
| Net Profit Margin | 0.17 |
| Gross Profit Margin | 1.14 |
Exelixis Price To Sales Ratio is quite stable at the moment. Further, Exelixis Days Sales Outstanding is increasing over the last 8 years. Exelixis Price To Sales Ratio is quite stable at the moment.
Further, Exelixis Days Sales Outstanding is increasing over the last 8 years. The previous year's value of Exelixis Days Sales Outstanding was 75.49. They say, "Don't put all your eggs in one basket," but Exelixis might just be the basket worth considering for November 2024. With a robust current ratio of 6.08X, the company demonstrates strong liquidity, ensuring it can meet its short-term obligations with ease. The biotechnology firm boasts a net income of 207.76 million, highlighting its profitability in a competitive industry. Additionally, a low beta of 0.54 suggests that Exelixis stock is less volatile compared to the broader market, potentially offering a smoother ride for investors. As the company continues to leverage its impressive cash flow from operations of 333.32 million, it could be poised for promising growth, making it an intriguing option for those looking to diversify their portfolios..
Are Exelixis technical ratios showing a bounce-back?
Exelixis stock appears to be on the mend, with a recent variance of 5.65 suggesting a potential turnaround. This could be a positive sign for investors, indicating renewed interest and activity. While technical indicators like these offer insights into market sentiment, they should be considered alongside broader market trends and the company's fundamentals. Exelixis exhibits relatively low volatility, with a skewness of 3.07 and kurtosis of 13.92. Understanding these volatility trends can help investors make informed decisions.
During bear markets, increased volatility can affect Exelixis' stock price, prompting investors to adjust their portfolios. By incorporating volatility indicators, traders can better assess the stock's risk relative to market conditions, whether in bullish or bearish phases.As we look towards November, Exelixis presents a compelling opportunity for investors, especially with its current valuation aligning closely with its real value of
28.87. The analyst consensus remains optimistic, with a "Buy" rating supported by 9 strong buy recommendations. While the highest estimated target price of
28.59 suggests limited upside, the company's solid fundamentals and strategic initiatives could offer potential for growth. Investors should weigh these factors carefully, considering both the potential rewards and the inherent risks in the biotech sector..
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Aina Ster is a Member of Macroaxis Editorial Board. Aina delivers weekly perspective on ongoing market and economic trends, analysis and tips from predictive analysis to forecasting across various financial instruments.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Aina Ster do not own shares of Exelixis. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
[email protected]